title: [Anandamide and R-(+)-methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2-receptors].
abstract: It has been found that prior intravenous administration of the endocannabinoid anandamide (10 mg/kg) or its synthetic analogue R-(+)-methanadamide (5 mg/kg) prevents a development of ischemic and reperfusion arrhythmias in rats. The prior injection of the CB1 receptor antagonist, SR 141716A (3 mg/kg), did no affect the antiarrhythmic action of both cannabinoids. Pretreatment with the CB2 receptor antagonist, SR 144528 (1 mg/kg), completely abolished antiarrhythmic effect of anandamide and R-(+)-methanandamide. Both CB antagonist had no effect on the arrhythmias itself. Pretreatment with the NO-synthase inhibitor, L-NAME (50 mg/kg), had no effect on the antiarrhythmic action of cannabinoids. We therefore conclude that CB2 receptor stimulation increases the heart tolerance to ischemic and reperfusion arrhythmias.
authors.affiliation: Laboratory of Experimental Cardiology, Institute of Cardiology, Kyevskaya 111, 634050 Tomsk, Russia.
authors.forename: A V
authors.initials: AV
authors.lastname: Krylatov
authors.forename: R V
authors.initials: RV
authors.lastname: Uzhachenko
authors.forename: L N
authors.initials: LN
authors.lastname: Maslov
authors.forename: D S
authors.initials: DS
authors.lastname: Ugdyzhekova
authors.forename: N A
authors.initials: NA
authors.lastname: Bernatskaia
authors.forename: R
authors.initials: R
authors.lastname: Pertwee
authors.forename: G B
authors.initials: GB
authors.lastname: Stefano
authors.forename: A
authors.initials: A
authors.lastname: Makriyannis
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001095:Arachidonic Acids / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D001157:Arterial Occlusive Diseases / Q000150:complications; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000150:complications; D063388:Endocannabinoids; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications*; D015428:Myocardial Reperfusion Injury / Q000150:complications*; D053284:Polyunsaturated Alkamides; D051381:Rats; D017208:Rats, Wistar; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists*
chemical_list: D000889:Anti-Arrhythmia Agents; D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C088155:methanandamide; C078814:anandamide